Arnold Glassman, DO
Sports Medicine · Wilmington, DENPI 1669582219
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 16 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Impel Pharmaceuticals Inc. at 36.3% of the total. Reporting peaked in 2022 at $298 and has fallen 94.3% since, to $17 in 2023.
Across 16 payments — averaging $30.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Impel Pharmaceuticals Inc.$176
- Biodelivery Sciences International, Inc.$118
- Biohaven Pharmaceutical Holding Company Ltd.$76
- Daiichi Sankyo Inc.$41
- IBSA Pharma Inc.$23
- Scilex Pharmaceuticals Inc.$22
- plus $28 from 2 others
What the payments were for
- Food & beverage$47397%
- Education$123%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Impel Pharmaceuticals Inc. | 3 | $176 |
| Biodelivery Sciences International, Inc. | 5 | $118 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $76 |
| Daiichi Sankyo Inc. | 3 | $41 |
| IBSA Pharma Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Protega Pharmaceutials Inc | 1 | $17 |
| Pfizer | 1 | $11 |
How this compares
Too few sports medicine providers in Delawareto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 27 | $17,409 |
| Fentanyl | 50 | $4,269 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 149 | $3,279 |
| Morphine Sulfate ErMorphine Sulfate | 82 | $2,425 |
| Gabapentin | 106 | $1,727 |
| Tizanidine Hcl | 58 | $843 |
| Cyclobenzaprine Hcl | 51 | $591 |
| Oxycodone Hcl | 39 | $537 |
| Ibuprofen | 44 | $399 |
| Famotidine | 32 | $372 |
| Pregabalin | 24 | $362 |
| Diclofenac Sodium | 16 | $316 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 21 | $298 |
| EndocetOxycodone Hcl/Acetaminophen | 11 | $242 |
| Lactulose | 12 | $227 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Wilmington
- Matthew VoltzWilmington$831
- Barry BakstWilmington$200
- Claire SheltonWilmington$53
- Andrew ReismanWilmington$18
- Emelynn FajardoWilmington$15
- Michael AxeNewark$120K
- Joseph StraightNewark$6K
- Bradley BleyNewark$3K
- Evan CrainNewark$1K
- Craig SternbergNewark$131
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.